MCID: ACT020
MIFTS: 58

Acute T Cell Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Acute T Cell Leukemia

MalaCards integrated aliases for Acute T Cell Leukemia:

Name: Acute T Cell Leukemia 12 15
T-Cell Acute Lymphoblastic Leukemia 12 38 30 6 17
Leukemia, Acute T-Cell 13 41
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 74
Precursor T-Cell Lymphoblastic Lymphoma 74
Precursor T Lymphoblastic Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5603
KEGG 38 H00002
MeSH 45 D015459
NCIt 51 C3184
SNOMED-CT 69 77430005
ICD10 34 C91.5 C91.50

Summaries for Acute T Cell Leukemia

MalaCards based summary : Acute T Cell Leukemia, also known as t-cell acute lymphoblastic leukemia, is related to precursor t-cell acute lymphoblastic leukemia and acute lymphocytic leukemia. An important gene associated with Acute T Cell Leukemia is ABL1 (ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Human cytomegalovirus infection. The drugs Racepinephrine and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include t cells, thyroid and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Acute T Cell Leukemia

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to Acute T Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Related Disease Score Top Affiliating Genes
1 precursor t-cell acute lymphoblastic leukemia 33.2 ABL1 BAX BCL10 FBXW7 LMO1 NOTCH1
2 acute lymphocytic leukemia 31.9 NOTCH1 TAL1 TLX3
3 leukemia 30.8 ABL1 BAX NOTCH1 TAL1 TLX3
4 leukemia, acute myeloid 30.7 ABL1 CASP8 CXCL12 LPP MTOR NUP214
5 t-cell leukemia 30.5 BCL11B LMO1 NOTCH1 TAL1 TCL6 TLX3
6 lymphoma 30.3 BAX BCL10 BCL11B TCL6
7 lymphoma, non-hodgkin, familial 30.1 BAX BCL10 CASP8 CXCL12 NOTCH1
8 leukemia, chronic lymphocytic 30.1 BAX BCL10 CASP8 CXCL12 NOTCH1
9 leukemia, acute lymphoblastic 12.3
10 t-cell adult acute lymphocytic leukemia 11.5
11 myeloid leukemia 10.5
12 hematopoietic stem cell transplantation 10.4
13 glucocorticoid resistance, generalized 10.3
14 oral cavity cancer 10.2 BAX CASP8 PTEN
15 ataxia-telangiectasia 10.2
16 fanconi anemia, complementation group a 10.2
17 wilms tumor 5 10.2
18 langerhans cell histiocytosis 10.2
19 acute promyelocytic leukemia 10.2
20 wilms tumor 6 10.2
21 interleukin-7 receptor alpha deficiency 10.2
22 thrombosis 10.2
23 hemopericardium 10.2
24 pericardial effusion 10.2
25 pure red-cell aplasia 10.2
26 thymoma 10.2
27 histiocytosis 10.2
28 pancreatitis 10.2
29 paraplegia 10.2
30 xp22.3 microdeletion syndrome 10.2
31 breast adenocarcinoma 10.1 BAX CASP8 PTEN
32 lymphoblastic lymphoma 10.1
33 lymphocytic leukemia 10.1
34 hematologic cancer 10.1 ABL1 BAX CXCL12 MTOR NOTCH1
35 cervical cancer 10.1 BAX CASP8 MTOR NOTCH1 PTEN
36 autoimmune lymphoproliferative syndrome 10.1 CASP8 FASLG MTOR
37 leukemia, chronic lymphocytic 2 10.0
38 medulloblastoma 10.0
39 thrombophilia due to thrombin defect 10.0
40 wilms tumor 1 10.0
41 lymphoma, hodgkin, classic 10.0
42 myasthenia gravis 10.0
43 neuroblastoma 10.0
44 ocular motor apraxia 10.0
45 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.0
46 caronte 10.0
47 juvenile myelomonocytic leukemia 10.0
48 leukemia, chronic myeloid 10.0
49 aplastic anemia 10.0
50 intraocular pressure quantitative trait locus 10.0

Graphical network of the top 20 diseases related to Acute T Cell Leukemia:



Diseases related to Acute T Cell Leukemia

Symptoms & Phenotypes for Acute T Cell Leukemia

GenomeRNAi Phenotypes related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

27 (show all 28)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.87 LMO1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.87 MTOR
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.87 LPP MTOR
4 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.87 HSD17B1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.87 NOTCH1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.87 LPP
7 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.87 NOTCH1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.87 NOTCH1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.87 MTOR
10 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.87 HSD17B1 NOTCH1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.87 HSD17B1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.87 LPP
13 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.87 HSD17B1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.87 NOTCH1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.87 NOTCH1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.87 LPP
17 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.87 LMO1 MTOR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.87 LMO1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.87 LPP
20 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.87 NOTCH1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.87 LMO1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.87 NOTCH1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.87 HSD17B1 LMO1 LPP MTOR NOTCH1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.87 LPP
25 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.87 LMO1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.87 MTOR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.87 LPP
28 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.87 LPP

MGI Mouse Phenotypes related to Acute T Cell Leukemia:

47 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.4 ABL1 BAX BCL10 BCL11B CASP8 CXCL12
2 mortality/aging MP:0010768 10.36 ABL1 BAX BCL10 BCL11B CASP8 CXCL12
3 homeostasis/metabolism MP:0005376 10.32 ABL1 BAX BCL11B CASP8 FASLG FBXW7
4 immune system MP:0005387 10.31 ABL1 BAX BCL10 BCL11B CASP8 CXCL12
5 hematopoietic system MP:0005397 10.3 ABL1 BAX BCL10 BCL11B CASP8 CXCL12
6 endocrine/exocrine gland MP:0005379 10.28 ABL1 BAX BCL10 BCL11B CASP8 FASLG
7 cardiovascular system MP:0005385 10.22 ABL1 CASP8 CXCL12 FASLG FBXW7 MTOR
8 embryo MP:0005380 10.2 ABL1 BCL10 CASP8 FBXW7 MTOR NOTCH1
9 nervous system MP:0003631 10.1 ABL1 BAX BCL10 CASP8 CXCL12 FASLG
10 integument MP:0010771 10.08 BCL11B CASP8 FASLG FBXW7 NOTCH1 PTEN
11 liver/biliary system MP:0005370 10 ABL1 CASP8 CXCL12 FASLG FBXW7 NOTCH1
12 neoplasm MP:0002006 9.97 BAX BCL11B CASP8 FASLG FBXW7 NOTCH1
13 muscle MP:0005369 9.95 ABL1 BAX CASP8 CXCL12 MTOR NOTCH1
14 normal MP:0002873 9.86 ABL1 CXCL12 FASLG FBXW7 LMO1 MTOR
15 renal/urinary system MP:0005367 9.7 BAX CASP8 FASLG MTOR NOTCH1 PTEN
16 respiratory system MP:0005388 9.61 ABL1 BAX CASP8 FASLG FBXW7 MTOR
17 vision/eye MP:0005391 9.23 ABL1 BAX BCL11B FASLG FBXW7 HSD17B1

Drugs & Therapeutics for Acute T Cell Leukemia

Drugs for Acute T Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 232)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
2
Bupivacaine Approved, Investigational Phase 4,Phase 1,Phase 2 2180-92-9, 38396-39-3 2474
3
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
4
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
5
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
6
tannic acid Approved Phase 4 1401-55-4
7 Mydriatics Phase 4
8 Adrenergic beta-Agonists Phase 4
9 Central Nervous System Depressants Phase 4,Phase 1,Phase 2,Not Applicable
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Adrenergic Agonists Phase 4
12 Vasoconstrictor Agents Phase 4
13 Anti-Asthmatic Agents Phase 4
14 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Neurotransmitter Agents Phase 4,Phase 2
16 Sympathomimetics Phase 4
17 Anesthetics Phase 4,Phase 1,Phase 2,Not Applicable
18 Anesthetics, Local Phase 4,Phase 1,Phase 2,Not Applicable
19 Adrenergic alpha-Agonists Phase 4
20 Epinephryl borate Phase 4,Not Applicable
21 Bronchodilator Agents Phase 4
22 Adrenergic Agents Phase 4,Phase 2
23 Respiratory System Agents Phase 4
24 Calamus Phase 4
25
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
26
Daunorubicin Approved Phase 3,Phase 2,Not Applicable 20830-81-3 30323
27
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
28
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
29
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
30
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
31
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
32
Ichthammol Approved Phase 3,Phase 2,Phase 1 8029-68-3
33
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
34
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
35
Mercaptopurine Approved Phase 3,Phase 2,Not Applicable 50-44-2 667490
36
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
37
Pegaspargase Approved, Investigational Phase 3,Phase 2,Phase 1 130167-69-0
38
Thioguanine Approved Phase 3,Phase 2 154-42-7 2723601
39
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
40
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
41
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
42
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2 50-03-3
43
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 83-43-2 6741
44
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
45
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Not Applicable 2921-57-5
46
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Not Applicable 302-25-0
47
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-24-8 5755
48
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
49
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
50
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 Postoperative Analgesia After Elective Hip Surgery - Effect of Obturator Nerve Blockade Completed NCT03064165 Phase 4 Bupivacaine-epinephrine;Sodium Chloride 9mg/mL
2 Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine Recruiting NCT03293472 Phase 4 Ropivacaine;Bupivacaine
3 Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis Recruiting NCT03781310 Phase 4 Tocilizumab
4 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
5 Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
6 Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
7 Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III Completed NCT00483132 Phase 3 interferon alpha 2a
8 ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy Completed NCT00816049 Phase 3 6MPindividualized;6MPfixed
9 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed NCT00557193 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Etoposide;Lestaurtinib;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
10 Stopping Postpartum Vitamin A Supplementation: Missing Concealed Benefit Completed NCT02043223 Phase 2, Phase 3
11 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia Completed NCT00613457 Phase 3 dexamethasone;asparaginase;Asparaginase;cyclophosphamide;cytarabine;daunorubicin;doxorubicin;Etoposide;Ifosfamide;mercaptopurine;Methotrexate;prednisone;thioguanine;Vincristine;Vindesine
12 Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment Recruiting NCT02881086 Phase 3 Rituximab;Nelarabine;PEG-Asparaginase;Imatinib;Idarubicin;Dexamethasone;Cyclophosphamide;Fludarabine;Vincristine;Mercaptopurine;VP16;Daunorubicin (DNR);Methotrexate;Cytarabine;Vindesine;Adriamycin;Prednisolone
13 Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL Recruiting NCT01228331 Phase 2, Phase 3 Amsacrine;Clofarabine;Cyclophosphamide;Cytarabine;Daunorubicin hydrochloride;Dexamethasone;Doxorubicin hydrochloride;Etoposide phosphate;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Thioguanine;Vincristine sulfate
14 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting NCT03117751 Phase 2, Phase 3 Prednisone;Vincristine;Daunorubicin;Pegaspargase;Erwinase®;Rituximab;Cyclophosphamide;Cytarabine;Mercaptopurine;Dasatinib;Methotrexate;Blinatumomab;Ruxolitinib;Bortezomib;Dexamethasone;Doxorubicin;Etoposide;Clofarabine;Vorinostat;Idarubicin;Nelarabine
15 A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Recruiting NCT02716233 Phase 3 pegaspargase 1250 IU/m2 x 2;pegaspargase 2500 IU/m2 x 1
16 Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
17 Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 Recruiting NCT03643276 Phase 3 Blinatumomab;Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin;DAUNOrubicin Liposomal Injection [DaunoXome];Dexamethasone;Doxorubicin;Etoposide;Fludarabine Phosphate;Ifosfamide;6-Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Tioguanin;Vincristine;Vindesine;Erwinase
18 Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Recruiting NCT03007147 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Dexrazoxane Hydrochloride;Doxorubicin;Etoposide;Ifosfamide;Imatinib Mesylate;Leucovorin Calcium;Mercaptopurine;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisolone;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
19 Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Recruiting NCT01085617 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;imatinib mesylate;melphalan;mercaptopurine;methotrexate;nelarabine;pegaspargase;vincristine sulfate
20 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Recruiting NCT03020030 Phase 3 Pegaspargase;Erwinia asparaginase;Cyclophosphamide;CYTARABINE;DASATINIB;DEXAMETHASONE;Dexrazoxane;Doxorubicin;ETOPOSIDE;HYDROCORTISONE;LEUCOVORIN CALCIUM;MERCAPTOPURINE;METHOTREXATE;NELARABINE;Vincristine
21 International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia Active, not recruiting NCT01117441 Phase 3 PEG-L-asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine;daunoxome;fludarabine
22 Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Suspended NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
23 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
24 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL) Completed NCT00684619 Phase 2 Nelarabine
25 A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL Completed NCT02518113 Phase 1, Phase 2 LY3039478;Dexamethasone;Placebo
26 Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
27 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma Completed NCT00061048 Phase 2
28 Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) Completed NCT00687323 Phase 2 temozolomide
29 Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia Completed NCT00095381 Phase 2 forodesine hydrochloride (BCX-1777)
30 Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma Completed NCT00866749 Phase 2 Daunorubicin;Vincristine;PEG-asparaginase;Intrathecal Methotrexate;Cyclophosphamide;Cytarabine;Mercaptopurine;Methotrexate;Doxorubicin;Thioguanine
31 Dose-finding Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia Completed NCT02654860 Phase 1, Phase 2 Paracetamol 3%;Placebo injection containing Saline solution 0.9%;Hyperbaric Bupivacaine HCl 0.5%
32 Losartan Versus Atenolol for the Treatment of Marfan Syndrome Completed NCT00593710 Phase 2 Losartan;Atenolol
33 506U78 in Treating Patients With Refractory Hematologic Cancer Completed NCT00002970 Phase 2 nelarabine;methotrexate;cytarabine;therapeutic hydrocortisone
34 Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
35 Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed NCT00873093 Phase 2 L-asparaginase;doxorubicin hydrochloride;therapeutic hydrocortisone;vincristine sulfate;cytarabine;prednisone;bortezomib;pegaspargase;methotrexate;etoposide phosphate;cyclophosphamide;leucovorin calcium;High Dose MTX
36 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
37 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
38 A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting NCT03384654 Phase 2 Daratumumab;Vincristine;Prednisone;Doxorubicin;Cyclophosphamide;Cytarabine;6-mercaptopurine;Methotrexate
39 BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Recruiting NCT02763384 Phase 2 BL-8040;Nelarabine
40 Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma Recruiting NCT00501826 Phase 2 Doxorubicin;Cyclophosphamide;Cytarabine;Dexamethasone;Methotrexate;Vincristine;Nelarabine;Mesna;6-MP;Prednisone
41 Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Recruiting NCT03860844 Phase 2 Isatuximab SAR650984;Dexamethasone;Fludarabine;Cytarabine;Liposomal daunorubicin;Daunorubicin;Idarubicin;Filgrastim;Mitoxantrone;Doxorubicin;Vincristine;PEG Asparaginase;Cyclophosphamide;Etoposide;Methotrexate
42 Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Recruiting NCT03575325 Phase 2 CPX-351
43 Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia Recruiting NCT02767934 Phase 2
44 Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Recruiting NCT03504644 Phase 1, Phase 2 Venetoclax;Vincristine Liposomal
45 Lenvatinib and Pembrolizumab in DTC Recruiting NCT02973997 Phase 2 Lenvatinib
46 Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia Active, not recruiting NCT00792948 Phase 2 Cyclophosphamide;Cytarabine;Dasatinib;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Leucovorin Calcium;Methotrexate;Methylprednisolone;Prednisone;Sirolimus;Tacrolimus;Vincristine Sulfate
47 Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia Active, not recruiting NCT02484430 Phase 2 Sapanisertib
48 SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Active, not recruiting NCT01574274 Phase 2 SC-PEG;Oncaspar
49 Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia Not yet recruiting NCT03808610 Phase 1, Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine
50 Ruxolitinib Plus LVP in Patients With R/R ETP-ALL Not yet recruiting NCT03613428 Phase 1, Phase 2 Ruxolitinib;Vincristine;Prednisone

Search NIH Clinical Center for Acute T Cell Leukemia

Genetic Tests for Acute T Cell Leukemia

Genetic tests related to Acute T Cell Leukemia:

# Genetic test Affiliating Genes
1 T-Cell Acute Lymphoblastic Leukemia 30

Anatomical Context for Acute T Cell Leukemia

MalaCards organs/tissues related to Acute T Cell Leukemia:

42
T Cells, Thyroid, Bone, B Cells, Myeloid, Bone Marrow, Brain

Publications for Acute T Cell Leukemia

Articles related to Acute T Cell Leukemia:

(show top 50) (show all 915)
# Title Authors Year
1
Timosaponin A‑III induces autophagy of T‑cell acute lymphoblastic leukemia Jurkat cells via inhibition of the PI3K/Akt/mTOR pathway. ( 30896824 )
2019
2
WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia. ( 30911287 )
2019
3
A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia. ( 30850736 )
2019
4
Zebrafish MYC-induced leukemia models: unique in vivo systems to study B and T cell acute lymphoblastic leukemia. ( 30863529 )
2019
5
Fratricide-resistant CD1a-specific CAR T-cells for the treatment of cortical T-cell acute lymphoblastic leukemia. ( 30796021 )
2019
6
A unique phenotype of T-cell acute lymphoblastic leukemia in a patient with GATA2 haploinsufficiency. ( 30802360 )
2019
7
Prognostic miRNA classifiers in t cell acute lymphoblastic leukemia: Study protocol for a systematic review and meta-analysis of observational clinical studies. ( 30817574 )
2019
8
Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. ( 30836001 )
2019
9
MiR-101 represses T-cell acute lymphoblastic leukemia by targeting CXCR7/STAT3 axis. ( 30837035 )
2019
10
A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. ( 30755812 )
2019
11
Comprehensive Investigation of miRNome Identifies Novel Candidate miRNA-mRNA Interactions Implicated in T-Cell Acute Lymphoblastic Leukemia. ( 30763910 )
2019
12
Malignancy-Associated Hypercalcemia Related with Receptor Activator of NF-κB Ligand (RANKL) Expression in T-Cell Acute Lymphoblastic Leukemia. ( 30783036 )
2019
13
Mitochondria as emerging targets for therapies against T cell acute lymphoblastic leukemia. ( 30698851 )
2019
14
Regulatory network analysis reveals the oncogenesis roles of feed-forward loops and therapeutic target in T-cell acute lymphoblastic leukemia. ( 30646895 )
2019
15
A comprehensive catalog of LncRNAs expressed in T-cell acute lymphoblastic leukemia. ( 30648438 )
2019
16
T Cell Acute Lymphoblastic Leukemia as a Consequence of Thymus Autonomy. ( 30651344 )
2019
17
PTEN abnormalities predict poor outcome in children with T-cell acute lymphoblastic leukemia treated according to ALL IC-BFM protocols. ( 30614545 )
2019
18
An integrated transcriptome analysis in T-cell acute lymphoblastic leukemia links DNA methylation subgroups to dysregulated TAL1 and ANTP homeobox gene expression. ( 30575306 )
2019
19
The rare translocation t(14;21)(q11;q22) detected in a Moroccan patient with T-cell acute lymphoblastic leukemia. ( 30533380 )
2019
20
The depletion of PHF6 decreases the drug sensitivity of T-cell acute lymphoblastic leukemia to prednisolone. ( 30551478 )
2019
21
Clinical and biological relevance of genetic alterations in pediatric T-cell acute lymphoblastic leukemia in Taiwan. ( 30280491 )
2019
22
IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update. ( 30249539 )
2019
23
Erratum: Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum]. ( 29443320 )
2018
24
Study of NOTCH1 and FBXW7 Mutations and Its Prognostic Significance in South Indian T-Cell Acute Lymphoblastic Leukemia. ( 29200162 )
2018
25
Hepatic leukemia-associated macrophages exhibit a pro-inflammatory phenotype in Notch1-induced acute T cell leukemia. ( 29030004 )
2018
26
Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels. ( 29278703 )
2018
27
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. ( 29047158 )
2018
28
Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. ( 29949919 )
2018
29
A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing. ( 29954933 )
2018
30
Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia. ( 29948644 )
2018
31
In vitro combinatorial anti-proliferative and immunosuppressive effects of Brucea javanica extract with CX-4945 and imatinib in human T-cell acute lymphoblastic leukemia cells. ( 29966986 )
2018
32
MicroRNA expression and activity in T-cell acute lymphoblastic leukemia. ( 29435192 )
2018
33
<i>WT1</i> loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia. ( 29170254 )
2018
34
PTPN22 Silencing in Human Acute T-Cell Leukemia Cell Line (Jurkat Cell) and its Effect on the Expression of miR-181a and miR-181b. ( 30023329 )
2018
35
Glycoproteomic analysis of MGL binding proteins on acute T cell leukemia cells. ( 30582698 )
2018
36
The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience. ( 30701921 )
2018
37
Retinal and Preretinal Hemorrhages in a Patient Receiving Hyper-CVAD Chemotherapy for T-Cell Acute Lymphoblastic Leukemia. ( 30627471 )
2018
38
miR-200b promotes cell proliferation and invasion in t-cell acute Lymphoblastic leukemia through NOTCH1. ( 30574752 )
2018
39
CRLF2 expression associates with ICN1 stabilization in T-cell acute lymphoblastic leukemia. ( 30578688 )
2018
40
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. ( 30552401 )
2018
41
T-cell acute lymphoblastic leukemia express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development. ( 30514801 )
2018
42
CD47 agonist peptide pkhb1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells. ( 30460757 )
2018
43
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. ( 30404791 )
2018
44
Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. ( 30407885 )
2018
45
High-dose methotrexate vs. Capizzi methotrexate for the treatment of childhood T-cell acute lymphoblastic leukemia. ( 30416957 )
2018
46
Loss of miR-146b-5p promotes T cell acute lymphoblastic leukemia migration and invasion via the IL-17A pathway. ( 30362152 )
2018
47
USP7 deubiquitinates and stabilizes NOTCH1 in T-cell acute lymphoblastic leukemia. ( 30370059 )
2018
48
Knockdown of MAML1 inhibits proliferation and induces apoptosis of T-cell acute lymphoblastic leukemia cells through SP1-dependent inactivation of TRIM59. ( 30370525 )
2018
49
NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia (T-ALL). ( 30387229 )
2018
50
Co-operation of ABT-199 and gemcitabine in impeding DNA damage repair and inducing cell apoptosis for synergistic therapy of T-cell acute lymphoblastic leukemia. ( 30320607 )
2018

Variations for Acute T Cell Leukemia

ClinVar genetic disease variations for Acute T Cell Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BCL10 NM_003921.4(BCL10): c.136_137insA (p.Ile46Asnfs) insertion Pathogenic rs387906351 GRCh37 Chromosome 1, 85736511: 85736511
2 BCL10 NM_003921.4(BCL10): c.136_137insA (p.Ile46Asnfs) insertion Pathogenic rs387906351 GRCh38 Chromosome 1, 85270828: 85270828
3 BAX NM_138761.3(BAX): c.199G> A (p.Gly67Arg) single nucleotide variant Pathogenic rs398122513 GRCh37 Chromosome 19, 49459056: 49459056
4 BAX NM_138761.3(BAX): c.199G> A (p.Gly67Arg) single nucleotide variant Pathogenic rs398122513 GRCh38 Chromosome 19, 48955799: 48955799
5 BAX NM_138761.3(BAX): c.115_121delGGGGGGG (p.Gly39Argfs) deletion Pathogenic rs398122840 GRCh37 Chromosome 19, 49458972: 49458978
6 BAX NM_138761.3(BAX): c.115_121delGGGGGGG (p.Gly39Argfs) deletion Pathogenic rs398122840 GRCh38 Chromosome 19, 48955715: 48955721
7 ABL1 Translocation Pathogenic GRCh37 Chromosome 9, 133709770: 133709771

Copy number variations for Acute T Cell Leukemia from CNVD:

7 (show top 50) (show all 91)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21835 1 16200000 23900000 Copy number CHD5 T-cell acute lymphoblastic leukemia
2 21836 1 16200000 23900000 Copy number HES2 T-cell acute lymphoblastic leukemia
3 21837 1 16200000 23900000 Copy number HES3 T-cell acute lymphoblastic leukemia
4 32217 1 34600000 44100000 Copy number T-cell acute lymphoblastic leukemia
5 34248 1 5400000 7200000 Deletion T-cell acute lymphoblastic leukemia
6 38166 10 1 3800000 Copy number T-cell acute lymphoblastic leukemia
7 41844 10 24600000 31300000 Copy number ADARB2 T-cell acute lymphoblastic leukemia
8 41845 10 24600000 31300000 Copy number PFKP T-cell acute lymphoblastic leukemia
9 41846 10 24600000 31300000 Copy number PITRM1 T-cell acute lymphoblastic leukemia
10 41847 10 24600000 31300000 Copy number WDR37 T-cell acute lymphoblastic leukemia
11 46873 10 87900000 92900000 Loss PTEN T-cell acute lymphoblastic leukemia
12 48336 11 1 2800000 Gain IGF2 T-cell acute lymphoblastic leukemia
13 48337 11 1 2800000 Gain hsa-mir-675 T-cell acute lymphoblastic leukemia
14 48490 11 1 52900000 Duplication T-cell acute lymphoblastic leukemia
15 53563 11 31000000 36400000 Copy number WT1 T-cell acute lymphoblastic leukemia
16 57103 11 63100000 67100000 Gain MAP4K2 T-cell acute lymphoblastic leukemia
17 57104 11 63100000 67100000 Gain RASGRP2 T-cell acute lymphoblastic leukemia
18 60336 11 85300000 87900000 Loss PICALM T-cell acute lymphoblastic leukemia
19 60878 11 92800000 110400000 Copy number ATM T-cell acute lymphoblastic leukemia
20 61471 12 1 14800000 Deletion T-cell acute lymphoblastic leukemia
21 61531 12 1 35400000 Duplication T-cell acute lymphoblastic leukemia
22 61611 12 10000000 12600000 Loss CDKN1B T-cell acute lymphoblastic leukemia
23 61613 12 10000000 12600000 Loss hsa-mir-614 T-cell acute lymphoblastic leukemia
24 61779 12 10100000 14800000 Copy number CDKN1B T-cell acute lymphoblastic leukemia
25 74382 13 105800000 109100000 Gain TNFSF13B T-cell acute lymphoblastic leukemia
26 78375 13 50900000 55300000 Deletion DLEU7 T-cell acute lymphoblastic leukemia
27 78376 13 50900000 55300000 Deletion KCNRG T-cell acute lymphoblastic leukemia
28 82826 14 15600000 23600000 Deletion T-cell acute lymphoblastic leukemia
29 88309 6 135544145 135582003 Copy number MYB T-cell acute lymphoblastic leukemia
30 104069 16 66700000 70800000 Deletion CTCF T-cell acute lymphoblastic leukemia
31 108732 17 22200000 28800000 Duplication T-cell acute lymphoblastic leukemia
32 109390 17 25800000 31800000 Copy number NF1 T-cell acute lymphoblastic leukemia
33 109749 17 28800000 35400000 Deletion T-cell acute lymphoblastic leukemia
34 111430 17 3600000 6800000 Loss NALP1 T-cell acute lymphoblastic leukemia
35 115247 17 55600000 58400000 Gain MSI2 T-cell acute lymphoblastic leukemia
36 115248 17 55600000 58400000 Gain VEZF1 T-cell acute lymphoblastic leukemia
37 115617 17 58400000 59900000 Gain MAP3K3 T-cell acute lymphoblastic leukemia
38 115618 17 58400000 59900000 Gain SMURF2 T-cell acute lymphoblastic leukemia
39 115619 17 58400000 59900000 Gain hsa-mir-633 T-cell acute lymphoblastic leukemia
40 115878 17 59900000 64600000 Gain PRKCA T-cell acute lymphoblastic leukemia
41 116600 17 68400000 72200000 Gain GPR142 T-cell acute lymphoblastic leukemia
42 116601 17 68400000 72200000 Gain GPRC5C T-cell acute lymphoblastic leukemia
43 121278 18 41800000 46400000 Loss SMAD4 T-cell acute lymphoblastic leukemia
44 124174 19 1 6900000 Gain MKNK2 T-cell acute lymphoblastic leukemia
45 131214 19 53800000 57600000 Gain FUT2 T-cell acute lymphoblastic leukemia
46 131215 19 53800000 57600000 Gain RASIP1 T-cell acute lymphoblastic leukemia
47 133723 19 6900000 12600000 Gain INSR T-cell acute lymphoblastic leukemia
48 133733 19 6900000 13900000 Deletion T-cell acute lymphoblastic leukemia
49 140125 2 19200000 27900000 Copy number NCOA1 T-cell acute lymphoblastic leukemia
50 140126 2 19200000 27900000 Copy number TP53I3 T-cell acute lymphoblastic leukemia

Expression for Acute T Cell Leukemia

Search GEO for disease gene expression data for Acute T Cell Leukemia.

Pathways for Acute T Cell Leukemia

Pathways related to Acute T Cell Leukemia according to KEGG:

38
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 BAX CASP8 CXCL12 FASLG MTOR PTEN
2
Show member pathways
12.72 BAX CASP8 FASLG MTOR NOTCH1 PTEN
3
Show member pathways
12.71 ABL1 BCL10 CASP8 CXCL12 FASLG
4
Show member pathways
12.49 ABL1 BAX FASLG MTOR PTEN
5 12.34 ABL1 MTOR NOTCH1 PTEN
6
Show member pathways
12.23 BAX FASLG MTOR PTEN
7 12.23 BCL10 BCL11B CXCL12 FASLG TAL1
8
Show member pathways
12.21 ABL1 BAX CASP8 PTEN
9
Show member pathways
12.09 BAX CASP8 FASLG FBXW7
10 12 BAX BCL10 CASP8 FASLG
11 11.95 ABL1 BAX CASP8 CXCL12 FASLG MTOR
12
Show member pathways
11.83 ABL1 BAX CASP8 FASLG PTEN
13
Show member pathways
11.66 BAX CASP8 FASLG
14 11.62 ABL1 BAX FASLG PTEN
15 11.55 BAX CASP8 FASLG
16 11.54 ABL1 BAX CASP8 MTOR PTEN
17 11.49 FBXW7 NOTCH1 PTEN
18 11.21 BAX CASP8 PTEN

GO Terms for Acute T Cell Leukemia

Cellular components related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 ABL1 CASP8 FBXW7 LMO1 MTOR NOTCH1
2 nucleus GO:0005634 9.53 ABL1 BAX BCL10 BCL11B CASP8 FASLG
3 postsynaptic cytosol GO:0099524 9.16 MTOR PTEN

Biological processes related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.97 BAX CASP8 CXCL12 FBXW7 NUP214
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.89 ABL1 FBXW7 NOTCH1 PTEN
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.83 ABL1 BCL10 CASP8 FASLG
4 neuron migration GO:0001764 9.79 BAX CXCL12 TLX3
5 regulation of cell cycle GO:0051726 9.78 ABL1 BAX NUP214 PTEN
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.77 BAX CASP8 FASLG
7 apoptotic signaling pathway GO:0097190 9.74 BAX CASP8 FASLG
8 neuron differentiation GO:0030182 9.73 ABL1 NOTCH1 TAL1 TLX3
9 extrinsic apoptotic signaling pathway GO:0097191 9.67 BAX CASP8 FASLG
10 cardiac muscle tissue development GO:0048738 9.62 MTOR PTEN
11 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.61 CASP8 FASLG
12 positive regulation of ubiquitin-dependent protein catabolic process GO:2000060 9.61 FBXW7 PTEN
13 negative regulation of cell size GO:0045792 9.58 MTOR PTEN
14 positive regulation of neuron death GO:1901216 9.58 ABL1 CASP8 MTOR
15 alpha-beta T cell differentiation GO:0046632 9.56 ABL1 BCL11B
16 B cell apoptotic process GO:0001783 9.55 BAX BCL10
17 T cell apoptotic process GO:0070231 9.51 BCL10 FASLG
18 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.5 BAX CASP8 FASLG
19 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.46 BAX CASP8
20 apoptotic process involved in embryonic digit morphogenesis GO:1902263 9.37 BAX NOTCH1
21 regulation of hematopoietic stem cell differentiation GO:1902036 9.33 ABL1 LMO1 TAL1
22 retinal cell programmed cell death GO:0046666 9.26 BAX FASLG
23 post-embryonic development GO:0009791 9.26 ABL1 BAX BCL11B MTOR
24 positive regulation of apoptotic process GO:0043065 9.1 ABL1 BAX BCL10 FASLG NOTCH1 PTEN
25 apoptotic process GO:0006915 10.01 ABL1 BAX BCL10 CASP8 FASLG PTEN

Molecular functions related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 ABL1 BAX BCL10 BCL11B CASP8 CXCL12
2 death receptor binding GO:0005123 9.16 CASP8 FASLG
3 enzyme binding GO:0019899 9.02 BCL10 NOTCH1 PHF6 PTEN TAL1

Sources for Acute T Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....